NanoViricides Stock Price. Everything You Need To Know About The NanoViricides Stock!
NanoViricides, Inc. is a development stage company that engages in the development of nanomedicine drugs to combat viruses. The company has a workforce of 17 full-time employees and is headquartered in Shelton, Connecticut. The firm went IPO on August 12th, 2004.
NanoViricides, Inc. is focused on the discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The firm’s nanoviricide technology enables direct attacks at multiple points on a virus particle, and it also allows attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide.
NanoViricides, Inc. is currently developing an antiviral drug candidate, NV-CoV-2, for the treatment of COVID-19 infected sick persons. The firm’s other clinical drug candidate, NV-HHV-101, is a skin cream for the treatment of shingles rash. Additionally, the company offers several pre-clinical drug development programs, including Herpes Simplex Viruses (HSV-1 that causes cold sores, and HSV-2 that causes genital ulcers), HIV/AIDS, Influenza, Dengue viruses, and Ebola/Marburg.
It is important to research NanoViricides, Inc. and stay up-to-date with the latest news and developments in the nanomedicine drugs industry. By keeping an eye on the stock price today and premarket, as well as shares and market cap, investors can gain valuable insight into the company’s performance and make informed investment decisions. Remember, investing always carries risk and investors should carefully consider their options before making any investment decisions. As a friendly reminder, this information is for educational purposes only and should not be considered financial advice.
NanoViricides Stock Price. Everything You Need To Know About The NanoViricides Stock! performance - Employees 17
- Company HQ Shelton
- Website http://www.nanoviricides.com/
- NNVC Asset Type Common Stock
- NNVC Market Capitalization 13.5M
- Earnings Per Share -0.8
- Dividends Per Share None
- Dividend Date 2019-09-24
- Quarterly Earnings Growth 0
NanoViricides is a promising stock in the biopharmaceutical industry that retail investors from Malaysia, Thailand, Indonesia, and Vietnam can consider for investment. As an innovative company, NanoViricides is focused on developing nanomedicines to effectively combat a wide range of viral infections. With their cutting-edge technology and extensive research, NanoViricides has the potential to revolutionize the medical field and provide effective treatment options for various viruses. Retail investors can benefit from investing in this stock by gaining exposure to a growing industry and potentially earning substantial returns. To invest in NanoViricides from Malaysia, Thailand, Indonesia, and Vietnam, investors can leverage Zorion’s user-friendly investment platform, which provides valuable insights, recommendations, and educational resources for making informed investment decisions. Expand your investment portfolio and explore the exciting opportunities offered by NanoViricides through Zorion.
